Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of severe hypertension with methyldopa.

Literature DB >> 13952341

Treatment of severe hypertension with methyldopa.

M HAMILTON, H KOPELMAN.

Abstract

Entities: Chemical Disease

Keywords: ANTIHYPERTENSIVE AGENTS

Mesh：

Substances：

Year: 1963 PMID： 13952341 PMCID： PMC2123398 DOI： 10.1136/bmj.1.5324.151

Source DB: PubMed Journal: Br Med J ISSN： 0007-1447

× No keyword cloud information.

10 in total

1. Methyldopa in the treatment of hypertension.

Authors: R I BAYLISS; E A HARVEY-SMITH
Journal: Lancet Date: 1962-04-14 Impact factor: 79.321

2. Another hypotensive agent--methyldopa.

Authors: D DALEY; B EVANS
Journal: Br Med J Date: 1962-07-21

3. Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension.

Authors: L GILLESPIE; J A OATES; J R CROUT; A SJOERDSMA
Journal: Circulation Date: 1962-02 Impact factor: 29.690

4. Serotonin synthesis in carcinoid patients. Its inhibition by alpha-methyl-dopa, with measurement of associated increases in urinary 5-hydroxytryptophan.

Authors: A SJOERDSMA; J A OATES; P ZALTZMAN; S UDENFRIEND
Journal: N Engl J Med Date: 1960-09-22 Impact factor: 91.245

5. Clinical pharmacology of newer anthypertensive agents, monoamine oxidase and decarboxylase inhibitors, bretvlium tosvlate, and guanethidine.

Authors: L GILLESPIE
Journal: Ann N Y Acad Sci Date: 1960-10-11 Impact factor: 5.691

6. [Inhibition of serotonin formation by alpha-methyl-DOPA].

Authors: E WESTERMANN; H BALZER; J KNELL
Journal: Naunyn Schmiedebergs Arch Exp Pathol Pharmakol Date: 1958

7. Hypertension: treated and untreated; a study of 400 cases.

Authors: A W LEISHMAN
Journal: Br Med J Date: 1959-05-30

8. Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine.

Authors: T L SOURKES
Journal: Arch Biochem Biophys Date: 1954-08 Impact factor: 4.013

9. Decarboxylase inhibition and blood pressure reduction by alpha-methyl-3,4-dihydroxy-DL-phenylalanine.

Authors: J A OATES; L GILLESPIE; S UDENFRIEND; A SJOERDSMA
Journal: Science Date: 1960-06-24 Impact factor: 47.728

10. Agranulocytosis caused by methyl dopa (Aldomet).

Authors: G P HALLWRIGHT
Journal: N Z Med J Date: 1961-12

10 in total

13 in total

1. METHYLDOPA IN TREATMENT OF SEVERE TOXAEMIA OF PREGNANCY.

Authors: S F HANS; H KOPELMAN
Journal: Br Med J Date: 1964-03-21

2. METHYLDOPA IN TREATMENT OF HYPERTENSION DUE TO CHRONIC RENAL DISEASE.

Authors: R G LUKE; A C KENNEDY
Journal: Br Med J Date: 1964-01-04

3. Methyldopa and depression.

Authors: A G FULLERTON; D MORTON-JENKINS
Journal: Br Med J Date: 1963-02-23

4. Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison.

Authors: B N Prichard; A W Johnston; I D Hill; M L Rosenheim
Journal: Br Med J Date: 1968-01-20

5. To-day's Drugs.

Authors:
Journal: Br Med J Date: 1963-04-13

6. Methyldopa in Hypertension.

Authors:
Journal: Br Med J Date: 1963-02-02

7. Hyperpyrexia During Treatment with Methyldopa.

Authors: V M Montegriffo
Journal: Br Med J Date: 1963-07-06

8. The effects of atenolol (tenormin) and methyldopa on simple tests of central nervous function.

Authors: P F Bayliss; S M Duncan
Journal: Br J Clin Pharmacol Date: 1975-12 Impact factor: 4.335

9. Methyldopa hepatitis. Report of three cases.

Authors: A M Hoyumpa; A M Connell
Journal: Am J Dig Dis Date: 1973-03

10. Some aspects of the long-term treatment of severe hypertension with methyldopa.

Authors: M Hamilton
Journal: Postgrad Med J Date: 1968-01 Impact factor: 2.401